A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.
Also called NCT01713530
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 274 participants
- Sponsor
- Registry
-
NCT01713530 -
2012-002346-20
-
- Other papers using this trial's data
- Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Algeria, Austria, France, Norway
- Registry status
- Completed
Technical summary
Registry record NCT01713530. Randomized; no masking; primary purpose treatment. Start 2013-02-21 (actual); primary completion 2014-01-09 (actual). Results posted on 2015-11-17.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin
- Condition
- Diabetes
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin degludec/insulin aspart
- Intervention (Drug)
- insulin degludec
- Intervention (Drug)
- insulin aspart
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct01713530- Content hash
60640c0fb48880d99e14c9166f9ca426f0db3b124386e4e160f9a21d370f5e63